Form 8-K - Current report:
SEC Accession No. 0001193125-24-226929
Filing Date
2024-09-26
Accepted
2024-09-26 16:13:00
Documents
14
Period of Report
2024-09-26
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d713439d8k.htm   iXBRL 8-K 34301
2 EX-99.1 d713439dex991.htm EX-99.1 8651
  Complete submission text file 0001193125-24-226929.txt   166875

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20240926.xsd EX-101.SCH 2869
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20240926_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20240926_pre.xml EX-101.PRE 10825
16 EXTRACTED XBRL INSTANCE DOCUMENT d713439d8k_htm.xml XML 3507
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 241329103
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)